Search

for
Search:

Research

5 / 1000+ results

research Interaction between estrogens and androgen receptor genes microsatellites, prostate-specific antigen and androgen receptor expressions in breast cancer

6 citations , January 2010 in “Neoplasma”

In this study, researchers found that shorter CA repeats in the ERbeta gene are correlated with PSA expression, and PSA immunoexpression is associated with increased disease-free survival in breast cancer.

research Androgen receptor expression in male pattern baldness patients

January 2012 in “Chinese Journal of Aesthetic Medicine”

This study found that in hair follicles, androgen receptor expression is stronger in the hair loss and transitional areas compared to the occipital region, suggesting a role in male pattern baldness.

research The Expressions of Androgen Receptors and Estrogen Receptors in Bald and Non-bald Area of Androgenic Alopecia

1 citations , January 2002 in “Journal of Clinical Dermatology”

This study found that androgen receptors were more prevalent in bald areas compared to non-bald areas in individuals with androgenic alopecia, suggesting a link between increased local androgen activity and hair loss.

research Skeletal Site-Dependent Expression of the Androgen Receptor in Human Osteoblastic Cell Populations

123 citations , December 1997 in “Calcified Tissue International”

This study concluded that higher androgen levels in males and specific skeletal sites may contribute to differences in skeletal morphology, with glucocorticoids, E2, and D3 enhancing androgen receptor expression and mitogenic action in human osteoblastic cells.

research A Study of the androgen receptor gene polymorphism and the level of expression of the androgen receptor in androgenetic alopecia among Egyptians

January 2009 in “Egyptian Journal of Medical Human Genetics”

This study, conducted among Egyptians, found a borderline significant association between the Stul polymorphism of the androgen receptor gene and androgenetic alopecia in males, with higher androgen receptor expression in balding scalp areas.

View more "androgen receptor expressions" in research →

Community Join

5 / 1000+ results

community Fluridil degrades the androgen receptor.

in Research/Science 12 upvotes 1 year ago

Fluridil degrades androgen receptors, which are prevalent in the scalp and other tissues. People with androgenetic alopecia (AGA) may have higher expression of these receptors and 5AR activity in affected scalp areas.

community Dutasteride: More Than a DHT Reducer – A Potential Androgen Receptor Inhibitor?

in Finasteride/Dutasteride 31 upvotes 1 year ago

Dutasteride may inhibit androgen receptors in addition to reducing DHT, potentially explaining its effectiveness over finasteride for hair loss. Concerns about its impact on muscle growth are debated, with some suggesting no significant effects.

community Is there a topical androgen receptor blocker so we don't have to fuck with the enzyme and destroy our allopregnanolone, but go and hit the end target straight?

in Treatment 44 upvotes 2 years ago

The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.

community GT20029 Will Replace Finasteride For Hair Loss

58 upvotes 4 months ago

GT20029 shows promise as a topical treatment for hair loss, potentially replacing finasteride for some due to its low systemic exposure and ability to degrade androgen receptors. However, skepticism remains about its long-term efficacy and availability, with some users expressing doubt about new treatments consistently failing to reach the market.

community A new study by Deng and colleagues set out to explore differences between balding and non balding scalps...

39 upvotes 4 years ago

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

View more "androgen receptor expressions" in community →

Learn

7 / 800 results

learn Clascoterone

Topical androgen-receptor blocker, approved as an acne cream

What is clascoterone and how does it work against hair loss? Clascoterone blocks androgen receptors in the skin. It is approved only for acne; a scalp solution is still investigational for hair loss.

learn GT20029

Experimental topical drug designed to break down androgen receptors

What is GT20029 and how does it work as a topical anti-androgen for hair loss? GT20029 is an investigational topical androgen-receptor degrader. One 12-week Phase II trial in 180 Chinese men found two of four regimens beat placebo on hair count; it is not approved or available.

learn Cyproterone

a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor

learn Fluridil

How is Fluridil different from other DHT blockers like finasteride? Fluridil is a topical androgen-receptor blocker applied to the scalp, while finasteride is an oral 5-alpha-reductase inhibitor that lowers DHT throughout the body. Finasteride is FDA-approved and far better studied; Fluridil rests on one 43-man trial and is not licensed as a hair-loss medicine, so its long-term safety and effect size are unknown.

learn Bicalutamide

Nonsteroidal anti-androgen, originally a prostate cancer drug

Can bicalutamide stop DHT from shrinking your hair follicles? Bicalutamide blocks androgens at the receptor rather than lowering DHT, and some dermatologists prescribe it off-label for women with pattern hair loss, although its US label says it should not be used in women. The one randomised trial (74 women, 2025) found it added no benefit to oral minoxidil, and the drug needs liver monitoring because its label warns of severe and fatal liver injury; it is contraindicated in pregnancy.

learn KX-826

Kintor Pharmaceutical: KX-826, a New Name in Hair Loss Research KX-826 (pyrilutamide) is an experimental topical androgen receptor blocker from Kintor Pharmaceutical and is not approved as a medicine anywhere. Its first China Phase III trial did not beat placebo; the company reported in March 2026 that a later Phase III of a 1.0% formulation met its primary endpoint, but these results are company announcements, not peer-reviewed, and long-term safety is unknown.

learn Pyrilutamide

Experimental topical anti-androgen, also known as KX-826

View more "androgen receptor expressions" in learn →

Experts

— no results

Try a deeper search in experts →

Clinics

— no results

Try a deeper search in clinics →